CurrentUnitedHealthcarePolicy MMP373.32

Urogenital/Anogenital (UG/AG) Panels

Coverage and clinical policy for molecular syndromic (panel) testing of urogenital/anogenital infectious pathogens, including when expanded versus targeted panels are considered reasonable and necessary; applicable to UnitedHealthcare members and providers performing such testing.

Policy Summary

PayerUnitedHealthcare

PolicyUrogenital/Anogenital (UG/AG) Panels

Policy CodePolicy MMP373.32

Change TypeNo material change

Effective Date08/01/2025

Next Review DateN/A

Key ActionDocument high-risk exposure when panel testing is performed and prefer targeted testing when clinical concern involves only a few specific pathogens.

SourceLink

08/01/2025Effective date

Jul 9, 2025Last committee approval

1 of 12Page

Multiple codesCoding present

1,478MVP study n

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Covered when criteria described below are met according to LCD/LCA guidance or the coverage rationale:

Epidemiologic indication / high-risk exposure: Panel testing is reasonable and necessary when there is an epidemiologic indication or documented high-risk exposure to sexually transmitted pathogens (i.e., concern for multiple STIs due to a high-risk experience), even if the patient is asymptomatic.documented high-risk exposure

High-risk reason must be clearly documented in the medical record; follow applicable LCDs/LCAs where present.

When targeted testing is required instead of expanded panel: If the primary clinical concern is for a small number of specific pathogens based on signs or symptoms (for example, lesions suggestive of HSV), only a small targeted panel (e.g., HSV-1 and HSV-2) is expected; expanded panels in this scenario are NOT considered reasonable and necessary and will NOT be covered.targeted panel sufficient

Prefer targeted testing when clinical concern is limited to specific pathogens.

Diagnosis of infectious vaginosis/vaginitis: For diagnosis of infectious vaginosis or vaginitis, a panel (targeted or expanded) that includes a combination of at least two of the following organisms is reasonable and necessary: Gardnerella vaginalis; other BV-associated bacteria (such as Atopobium vaginae and/or Megasphaera types); Trichomonas vaginalis; and Candida species.>=2 of listed pathogens included/detected

Panel must include the specified combination of organisms.

Coverage considerations (evidence-based use in symptomatic patients)

Clinical utility and performance considerations described in studies

Interpretation and clinical correlation: Positive molecular panel results require clinical correlation because detection may represent colonization rather than active infection; providers should interpret results in the context of signs, symptoms, and clinical management implications.

From Clinical Utility section

Evidence of assay performance in symptomatic patients: Prospective multicenter and validation studies (e.g., Xpert Xpress MVP, Aptima BV/CV/TV, BD MAX Vaginal Panel) demonstrated high sensitivity and specificity for BV, VVC, and TV in symptomatic individuals, supporting use when identification will affect management; study results included high positive and negative percent agreement and sensitivities/specificities reported in the cited trials.symptomatic patient

See performance summaries in clinical studies; clinician- and self-collected vaginal swabs and urine were evaluated.

Expanded molecular syndromic panels for urogenital/anogenital infections are not covered when the clinical presentation or concern is limited to a small number of specific pathogens and a targeted test would address the clinical question. For example, when signs or symptoms point primarily to herpes simplex virus (e.g., a lesion suggestive of HSV), only a small targeted panel (e.g., HSV‑1 and HSV‑2) is expected; in these scenarios expanded panels are not considered reasonable and necessary and will not be covered.

No individual assays are explicitly listed as excluded in this excerpt, but study reports indicate important assay and sample limitations that can affect interpretation and coverage decisions. Some validation studies excluded or invalidated a subset of samples (for example, 4.3% of samples were initially invalidated in one BD MAX study, with some remaining invalid on repeat) and did not always evaluate clinical outcomes for discordant results; these performance and sample‑handling limitations should be considered when ordering and interpreting panel testing.

Information about FDA 510(k) clearance for specific nucleic acid‑based assays is provided for reference only. FDA clearance or approval alone is not a basis for coverage; the presence of an FDA‑cleared test in the marketplace does not automatically make it reasonable and necessary under this policy.

Use of an expanded panel is considered not medically necessary when the clinical presentation indicates testing for only a small number of specific pathogens and a targeted test would suffice. In such circumstances, clinicians should order a focused assay (for example, a targeted HSV panel for lesion evaluation) rather than an expanded syndromic panel.

Clinicians should interpret positive results from molecular panels with caution because detection does not always equal active infection. Panels may detect colonizing organisms or incidental pathogens that are not the cause of current symptoms; clinical correlation is required to avoid over‑diagnosis and unnecessary treatment.

Covered Indications

Epidemiologic indication or documented high-risk exposure

Panel testing is reasonable and necessary when documented high-risk exposure or epidemiologic indication exists, even in the absence of symptoms.

Documentation requirement: A clear, documented high-risk reason for testing (epidemiologic indication or potential exposure to STIs) must be present in the medical record to justify panel testing in asymptomatic individuals.documented high-risk exposure

Follow applicable LCDs/LCAs where present.

Diagnosis of infectious vaginosis/vaginitis

For diagnosis of infectious vaginosis/vaginitis, covered when the panel includes at least two of the specified organisms.

Organism requirement: The panel must include a combination of at least two of the following organisms: Gardnerella vaginalis; other BV-associated bacteria (e.g., Atopobium vaginae, Megasphaera types); Trichomonas vaginalis; Candida species.>=2 of listed organisms included/detected

Targeted or expanded panels meeting this requirement are reasonable and necessary for diagnosis of vaginosis/vaginitis.

Evaluation of symptomatic vaginitis/vaginosis and detection of urogenital STIs (specimens and population)

Covered for evaluation of symptomatic patients using appropriate specimen types.

Symptomatic population: Testing is intended for symptomatic individuals presenting with signs or symptoms of vaginitis or vaginosis (studies enrolled patients ≥14 years with symptoms).symptomatic

Document symptoms and specimen type in the medical record.

Acceptable specimen types: Specimen types evaluated and acceptable include clinician-collected vaginal swabs, self-collected vaginal swabs, endocervical swabs, and urine specimens as described in validation studies.document specimen type

Studies assessed clinician- and self-collected vaginal swabs and urine; document sample type on order/record.

Intended use: Use of molecular panels is supported when identification of BV, VVC, TV, or urogenital STIs (e.g., Chlamydia trachomatis, Neisseria gonorrhoeae) in symptomatic patients will inform clinical management.

Detection of vaginitis and sexually transmitted pathogens in urogenital samples

Includes use for detection of vaginitis and sexually transmitted pathogens in urogenital samples, and for workup when coinfection is suspected or screening per prevalence evidence.

Coinfection workup: Panel testing is reasonable when coinfection is suspected or when prevalence data indicate a meaningful likelihood of multiple pathogens (studies report high rates of coinfection and variable pathogen distribution by age/sex).clinical suspicion of coinfection or epidemiologic rationale

See prevalence studies documenting frequent coinfections and variable distributions.

Screening considerations: Panels may be used in contexts informed by prevalence studies (e.g., high positivity or coinfection rates) when results would affect patient management or follow-up.screening justified by prevalence/management impact

Refer to prevalence studies for local epidemiology considerations.

Coding

Applicable Procedure Codes (molecular panel CPT/HCPCS)CPT

0352U	Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected (Deleted 12/31/2024 - see CPT code 81515).
81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis.
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported.
81515	Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis (Effective 01/01/2025).

Applicable Diagnosis Codes (ICD-10-CM)ICD-10

A51.0	Primary genital syphilis.
A54.00	Gonococcal infection of lower genitourinary tract, unspecified.
A56.00	Chlamydial infection of lower genitourinary tract, unspecified.
A59.00	Urogenital trichomoniasis, unspecified.
A60.00	Herpesviral infection of urogenital system, unspecified.
B20	Human immunodeficiency virus [HIV] disease.
B37.31	Acute candidiasis of vulva and vagina.
Z11.3	Encounter for screening for infections with a predominantly sexual mode of transmission.
Z20.2	Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission.
Z72.51	High risk heterosexual behavior.

Referenced local coverage / MolDX documentsmixed

L36021	Molecular Diagnostic Tests (MDT)
L35160	MolDX: Molecular Diagnostic Tests (MDT)
L36807	MolDX: Molecular Diagnostic Tests (MDT)
L35025	MolDX: Molecular Diagnostic Tests (MDT)
L34519	Molecular Pathology Procedures
L35062	Biomarkers Overview
L39365	Genetic Testing in Oncology: Specific Tests

Panel definition threshold

Panel threshold> 1 pathogen

ContextUsed for UG/AG molecular testing to indicate a single assay detects more than one pathogen.

Coverage implicationPanels detecting >1 pathogen are evaluated under panel-specific coverage criteria and LCD/LCA guidance.

Provider Actions and Requirements

Prior Authorization

LCD/LCA Compliance and Coverage Rationale

Coverage must follow applicable CMS Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs). Where an LCD/LCA exists for molecular syndromic panels for infectious disease pathogen identification testing, providers must comply with that contractor's guidance. For states/territories without an applicable LCD/LCA or when the LCD/LCA is silent, the coverage rationale below applies: epidemiologic indication or documented high‑risk exposure may justify UG/AG panel testing even without symptoms; otherwise, prefer targeted testing for a limited set of pathogens and do not cover expanded panels when the clinical concern is limited to a few specific organisms.

Follow the specific LCD/LCA identified for Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing when present.
When LCDs/LCAs are absent or silent, apply the coverage rationale in this policy (see documentation and targeted testing guidance).

Note

Referenced Coding and MolDX Documents

This policy references MolDX and CMS billing and coding materials. Providers should consult the listed MolDX LCDs, billing & coding articles, and relevant CMS Lab NCDs for coding, billing, and coverage details. The presence of these references does not substitute for following contractor-specific rules where they apply.

See MolDX LCDs and Billing & Coding Articles (examples: L39038, A58747 and other MolDX items listed in policy references).
Consult contractor-specific guidance (MAC-level) for coding and billing procedures.

Prior Authorization

Follow Delegate Prior Authorization When Applicable

For UnitedHealthcare Medicare Advantage members where a delegate (e.g., delegated vendor or plan partner) manages utilization management and prior authorization, providers must follow the delegate's prior authorization processes and requirements.

When delegated, adhere to the delegate's PA submission process, timelines, and documentation requirements.
Failure to follow delegate PA processes may result in denial of coverage or claims processing delays.

Billing Rule

No Explicit Authorization or Billing Denial Triggers Present

This partial document does not specify any explicit provider actions that automatically trigger authorization or immediate billing denial beyond the LCD/LCA and UnitedHealthcare/delegate processes. Providers remain responsible for accurate claims submission and adherence to Medicare/contractor requirements.

No standalone authorization or billing-denial triggers are specified in this excerpt; follow LCD/LCA, UnitedHealthcare policy, and delegate rules as applicable.
Providers are responsible for accurate claims and appropriate supporting documentation.

Documentation Required

Documentation of High‑Risk Exposure

When testing is performed because of a documented high‑risk exposure (for example, epidemiologic indication or potential exposure to sexually transmitted pathogens), the reason must be clearly documented in the medical record to support coverage even in the absence of symptoms.

Document the specific high‑risk exposure or epidemiologic indication in the clinical record.
Include date, nature of exposure, and clinical rationale linking exposure to testing decision.

Documentation Required

Specimen Types and Symptomatic Status

Document the specimen type collected and the patient's symptomatic status. Studies supporting test performance include both clinician-collected and self-collected swabs; indicate which was used.

Record specimen type (e.g., clinician-collected vaginal swab, self-collected vaginal swab, respiratory specimen) on the claim and in the chart.
Record whether the patient was symptomatic or asymptomatic at the time of collection.

Billing Rule

Claims Submission and Delegated Prior Authorization

Claims must be submitted accurately using applicable CPT/CMS coding guidance referenced in this policy and MolDX/CMS materials. When prior authorization is managed by a delegate for Medicare Advantage members, follow the delegate's PA and claims submission instructions.

Use the CPT and billing guidance cited by MolDX and CMS for molecular syndromic panels.
When delegated, submit PA requests and claims per the delegate's process to avoid denials or delays.

Denial Risk

Prefer Targeted Testing Over Expanded Panels

Prefer targeted testing when the clinical concern is limited to a few specific pathogens (for example, lesions suggestive of HSV). Expanded syndromic panels are not considered reasonable and necessary and will not be covered when a small, focused panel would address the clinical question.

If signs and symptoms point to specific pathogens, order a targeted panel (e.g., HSV-1/HSV-2) rather than an expanded syndromic panel.
Expanded panels ordered primarily to detect a small number of suspected pathogens carry denial risk.

Step Therapy

Step Therapy / Sequencing

No step therapy or sequencing requirements are specified in this excerpt. Clinicians should interpret positive panel results carefully — additional confirmatory testing or clinical correlation may be necessary because panels can detect colonizers or non‑active organisms.

There are no stated step therapy prerequisites before panel testing in this policy excerpt.
Consider clinical context and potential need for confirmatory testing when panel results detect unexpected organisms.

Billing Rule

Claims Accuracy and Adherence to Medicare/Contractor Requirements

Providers must ensure claims are accurate and meet Medicare and contractor requirements. Coverage decisions follow Medicare statutes, NCDs, LCDs, and UnitedHealthcare policies; where delegate arrangements exist, follow the delegate's utilization management processes.

Adhere to Medicare source materials where conflicts with this policy arise — Medicare materials prevail.
When coverage is managed by a delegate, follow the delegate's utilization management and prior authorization rules.

Definitions

Panel

DefinitionA test that detects > 1 pathogen.

Use caseApplies to molecular assays designed to report multiple organism targets from a single specimen.

DistinctionDifferent from targeted tests that detect a single pathogen or a very small set of specified pathogens.

Syndromic Panel

DefinitionA test that simultaneously detects multiple different pathogens associated with similar and overlapping clinical symptomatology.

Clinical contextCommonly used for syndromes (e.g., vaginitis/vaginosis) where symptoms overlap across pathogens.

Performance noteProvides rapid, multiplexed results which may detect coinfections and improve diagnostic yield compared with clinician assessment alone.

Analytical Validity (AV)

DefinitionAssessment of a test's technical performance (sensitivity, specificity, accuracy, precision) to determine if it measures what it was designed to measure.

PurposeDetermines whether the assay reliably detects the intended targets under specified conditions.

Not clinical utilityAnalytical validity evaluates technical performance, not whether results change patient outcomes.

Clinical Utility (CU)

DefinitionThe ability of a test to provide information related to the patient's care and management and to inform treatment decisions.

Clinical implicationClinical utility assessment focuses on whether test results change management and improve health outcomes.

Interpretation cautionPositive results require clinical correlation because detection may represent colonization rather than active infection.

Clinical Validity (CV)

DefinitionAbility of a test to accurately and reliably detect the disease of interest in the defined population.

ScopeIncludes the test's diagnostic, prognostic, or predictive classification performance which may vary by population.

Not fixedClinical validity metrics can change depending on study methods and population tested.

Molecular syndromic panels

DescriptionMultiplex PCR/NAAT assays that detect multiple pathogens from a single specimen with rapid turnaround and often higher sensitivity than traditional methods.

CharacteristicsOften used in point-of-care and laboratory settings; may detect coinfections and have variable performance by pathogen and panel.

Performance examplesAssays such as BD MAX vaginal panel and Xpert Xpress MVP showed high sensitivity/specificity for BV, VVC, and TV in studies.

FDA-cleared nucleic acid-based tests

ExamplesCommercial assays cleared through FDA 510(k) for genitourinary pathogen detection include Aptima BV Assay, BD MAX Vaginal Panel, and Xpert Xpress MVP.

Purpose of mentionFDA-cleared tests are listed for informational purposes; FDA clearance alone is not a basis for coverage.

Policy notePresence of FDA-cleared assays in the literature does not override LCD/LCA or policy coverage criteria.

OpenPayer

Urogenital/Anogenital (UG/AG) Panels

Coverage Criteria

Covered Indications

Coding

Provider Actions and Requirements

Ordering Requirements

Not Covered

Definitions

Frequency Limits

Background